CliffBio
small molecule

CARBIDOPA AND LEVODOPA

CARBIDOPA; LEVODOPA

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameCARBIDOPA AND LEVODOPA
Active ingredientCARBIDOPA; LEVODOPA
Strength50MG;200MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2004
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.